Compare Innovative Industrial Properties Inc (IIPR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Medpace Holdings Inc — how do they compare? Innovative Industrial Properties Inc trades at $51.83 (market cap $1.43B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 11.8× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 14.64% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and Medpace Holdings Inc for 14 Days on average.
| IIPR | MEDP | |
|---|---|---|
Market Cap | $1.43B | $16.82B |
Volume | 394,222 | 223,093 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $630.19 |
52-Week Low | $44.58 | $393.42 |
Typical Hold Time | 86 Days | 14 Days |
Enterprise Value | $1.96B | $16.44B |
Dividend Yield | 14.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.92, up 1.35% with bearish technical signals but attractive valuation metrics including P/E of 11.75 and P/B of 0.83. The REIT reported mixed Q2 2026 earnings, beating expectations with $1.36 EPS versus $1.02 expected, while revenue declined to $266M in 2025. Recent news highlights a $245M mezzanine loan commitment and a $1.90 quarterly dividend, though cash flow turned negative in 2025.
The stock presents a high-yield opportunity with 13%+ dividend yield but faces tenant default risks and sector volatility. Analyst consensus is mixed with 36% buy ratings and $84.67 price target suggesting 63% upside, though technical indicators remain bearish. Regulatory catalysts and balance sheet strength provide potential upside amid cannabis REIT sector challenges.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
